

Effects of Valsartan and Telmisartan on the Lung Tissue Histology in Sensitized Rats

Manal A. Algaem¹, Intesar T. Numan², Saad A. Hussain^{2,*}

¹Department of Pharmacology, College of Pharmacy, Al-Basra University, Iraq

²Department of Pharmacology and Toxicology, College of Pharmacy, University of Baghdad, Baghdad, Iraq

*Corresponding author: saad_alzaidi@yahoo.com

Received July 02, 2013; Revised August 14, 2013; Accepted August 16, 2013

Abstract The renin-angiotensin system (RAS) was potentially implicated in the pathogenesis of pulmonary disorders through its involvement in inducing pro-inflammatory mediators in the lung tissues. The present study evaluates the effects of the angiotensin receptor blockers (ARBs), telmisartan and valsartan, on the histological changes of lung tissues in sensitized rats. Twenty-four Wistar female rats were randomly divided into four groups: A, negative control; B, valsartan-treated group; C, telmisartan-treated group and D, positive control. The rats in the groups B-D were sensitized and challenged with ovalbumin (OVA). Group A rats were sensitized and challenged with normal saline. Rats from groups B and C were treated with either valsartan or telmisartan (5mg/kg/day), respectively. The effects of administered ARBs on lung tissue structures were histologically evaluated. Treatment with telmisartan significantly attenuates the inflammatory and the hyper-proliferative changes in lung tissue after OVA-challenge, while valsartan did not show such effect. In conclusion, telmisartan demonstrates anti-inflammatory and anti-proliferative activities in sensitized rats, while valsartan lacks these effects.

Keywords: *telmisartan, valsartan, sensitization, inflammation, lung*

Cite This Article: Manal A. Algaem, Intesar T. Numan, and Saad A. Hussain, "Effects of Valsartan and Telmisartan on the Lung Tissue Histology in Sensitized Rats." *American Journal of Pharmacological Sciences* 1, no. 4 (2013): 56-60. doi: 10.12691/ajps-1-4-3.

1. Introduction

Airway disorders associated with persistent inflammation, such as chronic obstructive pulmonary disease (COPD) and asthma and recognized as chronic conditions; they are influenced by a combination of environmental, genetic and epigenetic components [1]. Inflammation of the airways plays a central role in the pathogenesis of asthma and COPD, and the clinical investigations showed a correlation between the presence of activated inflammatory cells (neutrophils, mast cells, and eosinophils), histological changes in pulmonary tissue with the development of airways hyper-reactivity [2]. Meanwhile, ongoing airway inflammation and associated airway remodeling played a pivotal role in the development of airway hyper-responsiveness and airflow limitations [3]. It was found that repeated allergen inhalation increased airway smooth muscle mass, pulmonary contractile protein expression and the contractility of tracheal smooth muscle; all indicative of airway smooth muscle remodeling [4]. A local renin-angiotensin system (RAS) exists in many human tissues including the lung, and angiotensin II (AgII) receptors are expressed in the pulmonary tissues [5]. Animal studies have indicated that Ag II receptor 1 (AgIIR1) is involved in Ang II effects including bronchoconstriction in guinea pigs [6]. It stimulates the release of pro-inflammatory

cytokines, activates nuclear factor kappa B (NF-kB), increases oxidant stress, suppress nitric oxide synthesis and behave as an inflammatory molecule [4]. It also induces inflammation through the production of reactive oxygen species, adhesion molecules, and inflammatory cytokines such as chemo-attractant protein-1 (MCP-1). MCP-1 acts as a central mediator of inflammatory response in hypertensive vascular disease [7]. Ag II also induces cyclooxygenase-2 (COX-2) synthesis and release [8]. Chronic inflammation of the central and peripheral airways was recognized as a central feature of many pulmonary disorders, including asthma and COPD and mostly associated with lung remodeling, parenchymal destruction and the development of emphysema [9]. The RAS was potentially implicated in the pathogenesis of pulmonary disorders through its involvement in inducing pro-inflammatory mediators in the lung tissues [10]. Pulmonary fibrosis is relevant to the pathogenesis of inflammatory lung diseases in two ways; first, fibrosis, which is a component of airway remodeling in asthma COPD [11]; second, it is now well recognized that a proportion of COPD patients have a syndrome of combined pulmonary fibrosis and emphysema with distinct clinical features [12]. Evidence for the involvement of pulmonary RAS in lung fibrosis comes from studies of broncho-alveolar lavage fluid from patients with inflammatory lung disorders, showing elevated angiotensin converting enzyme (ACE) levels [13]. In lung biopsies taken from patients with idiopathic lung

fibrosis, Li et al. [14] found an increased level of angiotensinogen protein and mRNA, which localized to areas of epithelial apoptosis and myofibroblast foci. These findings are supported by the work of Raupach et al. [15], who investigated the effects of the ARB AngII receptor blocker (ARB) irbesartan on an emphysema mouse model, finding benefits in histological emphysema severity, lung compliance and exercise capacity following treatment. The present study was designed to evaluate the effect of telmisartan and valsartan on the histology of pulmonary tissues in the airways of sensitized rats.

2. Materials and Methods

Twenty-four Wistar albino female rats (3 weeks old) weighing 180-250 g, obtained from the College of Pharmacy/University of Baghdad, were housed in the animal house, College of Pharmacy, University of Basra; they were maintained on normal conditions of temperature, humidity and light/dark cycle. They fed standard rodent pellet diet and they had free access to water. The local Research Ethics Committee in College of Pharmacy, University of Baghdad, approved the research protocol. The animals randomly allocated into four groups (each of 6 rats) according to the type of treatment; group A, treated with distilled water (negative control); group B, treated with valsartan (5mg/kg/day); group C, treated with telmisartan (5mg/kg/day); group D, treated with distilled water (0.5 ml/day) and kept as positive control. Both drugs and the vehicle (distilled water) administered orally as single daily doses using gavage tube. According to the methods of Xue et al [16], the rats in the positive control group and ARBs-treated groups (B-D) were sensitized by intraperitoneal injections on days 0 and 7 with 100 mg ovalbumin (OVA) and 100 mg Al(OH)₃ in 1 ml saline. On day 15, the rats were challenged with inhaled nebulized 1% OVA for 30 minutes, every other day for 30 days. Sixty minutes prior to OVA exposure, the rats in groups B-D were given orally valsartan, telmisartan or distilled water, respectively. The rats in the negative control group were sensitized and challenged with 0.9% saline, every other day for 30 days. Challenges took place in a chamber (20 cm × 30 cm × 40 cm) with free-breathing animals. After challenging the rats, they were killed by intraperitoneal injection of 50mg/kg phenobarbitone sodium and their lungs were extracted, fixed in 10% neutral buffered formalin and embedded in conventional paraffin. Sections were prepared and stained with Hematoxyline and Eosin (H&E) for structural and morphometric evaluation. For these measurements, photomicrographs of three fields from each section containing airways were taken using a digital camera (JVC TK-890-E; JVC, Yokohama, Japan) fitted to an Olympus BH-2 RFCA microscope (Olympus Optical Co. Ltd, Tokyo, Japan) [17]; thicknesses were measured using a calibrated micrometric analyzer at 8 different points on 2 to 3 different airways.

3. Statistical Analysis

Data were expressed as mean ± SD. The Statistical significance of the differences between various groups

was determined by Post-hoc test (LSD alpha 0.05) and one-way analysis of variance (ANOVA) using SPSS for Windows. Differences were considered statically significant for p -value < 0.05.

4. Results




Figure 1. Sections of lung tissue from negative control group stained with H&E (A, 4X; B, 10X). Clear bronchioles (b) and alveolar sac (as) without infiltration of inflammatory cell

Histopathological study of lung tissue in negative control group revealed the alveolar sac and bronchioles with normal epithelium (Figure 1). In sensitized rats (group D), the sections showed increased accumulation of inflammatory cells that occluded the bronchioles and the alveolar sac, with thickness of alveolar smooth muscle and trachea (Figure 2). In Figure 3, treatment of sensitized rats with telmisartan clearly shows improved histological appearance, decreases in infiltration with inflammatory cells, and relatively clear bronchial and alveolar sacs with remarkable decrease in the thickness of alveolar epithelium and tracheal smooth muscles. However, no remarkable improvement reported in lung tissue sections from group B (valsartan-treated) animals, where the histological appearance is comparable to that shown in positive control (group D) (Figure 4). As shown in Table 1, the mean thickness of alveolar smooth muscle in positive control group was significantly greater than that reported in negative control (118%, $P < 0.05$). Treatment with valsartan shows very small decrease in thickness which is comparable to that reported in positive control group and

significantly higher than that reported in negative control group (103%, $P<0.05$). Meanwhile, treatment with telmisartan significantly decreases the smooth muscle thickness compared with positive control group (46%) and that reported in valsartan-treated group (39%); this value was found comparable to that reported in negative control group ($P>0.05$). In Table 2, the mean thickness of trachea in positive control group was significantly higher than that reported in negative control (77.4%, $P<0.05$). Treatment with valsartan shows very small decrease in thickness of trachea in sensitized rats, which is comparable ($P>0.05$) to that reported in positive control group and significantly higher than that reported in negative control group (60.5%, $P<0.05$). Meanwhile, treatment with telmisartan significantly decreases the thickness of trachea compared with positive control group (36.5%) and that reported in valsartan-treated group (30%); this value was found comparable to that reported in negative control group ($P>0.05$).




Figure 2. Sections of lung tissue from positive control groups stained with H&E (40X); the section was filled with inflammatory cell (I), bronchioles (b) and alveolar sac (as) were filled with exudate and inflammatory cell




Figure 3. Sections of lung tissue from telmisartan-treated group stained with H&E (A, 40X; B, 10X); few inflammatory cell (I), the bronchioles (b) and alveolar sac (as) were nearly clear




Figure 4. Sections of lung tissue from valsartan-treated group stained with H&E (A, 40X; B, 10X); the section was filled with inflammatory cells (I), bronchioles (b) and alveolar sac (as) were filled with inflammatory exudate

Table 1. Effect of telmisartan and valsartan on thickness of alveolar smooth muscle in sensitized rats

Treatment groups	Mean thickness of alveolar smooth muscle (μm)
A (negative control)	6.1 ± 0.54^a
B (5mg/kg telmisartan)	7.6 ± 0.30^a
C (5mg/kg valsartan)	12.4 ± 1.63^b
D (positive control)	13.3 ± 2.08^b

Data are expressed as mean \pm SD; n=6 animals in each group; values with non-identical superscripts (a, b) are significantly different ($P<0.05$).

Table 2. Effect of treatment with telmisartan and valsartan on thickness of trachea in sensitized rats

Treatment groups	Mean thickness of trachea (μm)
A (negative control)	59.2 \pm 4.0 ^a
B (5mg/kg telmisartan)	66.7 \pm 2.5 ^a
C (5mg/kg valsartan)	95.0 \pm 5.8 ^b
D (positive control)	105.0 \pm 3.7 ^b

Data are expressed as mean \pm SD; n=6 animals in each group; values with non-identical superscripts (a,b) are significantly different ($P<0.05$).

5. Discussion

Repeated exposure of pulmonary tissues to sensitizing agents results in different degrees of airway remodeling. In addition to the recruitment of many types of inflammatory cells to the pulmonary tissues, airway remodeling also involves proliferation of smooth muscle cells, shading of epithelium and proliferation of the extracellular matrix, which is mostly attributed to the over expression of many growth factors including TGF- β 1 [18]. The present study confirms that repeated sensitization results in pulmonary tissue injury including proliferation of smooth muscle cells in the trachea and alveoli, as evidenced by the stained tissue sections and morphometric measurements. Although AngII can act as a weak bronchoconstrictor through its AT1R, it can act synergistically with endothelin-1 to produce more powerful contractions in bronchial bovine smooth muscles [19,20]. AngII can activate phospholipase A2 and the release of arachidonic acid from membrane phospholipids [21]. Arachidonic acid is then converted into thromboxane A2 by the action of cyclooxygenase and into leukotrienes by lipoxygenase [22]. The results of the present study was in tune with the previously mentioned one, where typical inflammatory response was evident in the tissue sections, in addition to the remodeling of the airways manifested as increased thickness of the smooth muscle layers in both trachea and alveoli. Airway remodeling is an integral part of bronchial hyper responsiveness, since it distorts and alters permanently the structure and caliber of the bronchi. These changes occur in response to persistent inflammation and include subepithelial fibrosis, hyperplasia of mucus glands, myofibroblast and smooth muscle proliferation and angiogenesis [23,24]. The present study has shown that telmisartan (5mg/kg/day) prevents and/or relieves allergen-induced inflammatory cells accumulation and excessive proliferation in lungs of ovalbumin-challenged rats, while valsartan do not show such type of activity when administered in equivalent doses to telmisartan for the same purpose. The anti-inflammatory effect of telmisartan in this model was reported for the first time; however, such anti-inflammatory activity was previously reported in other models of inflammation [25]. Although previous studies demonstrate the effectiveness of valsartan as anti-inflammatory agent in experimentally-induced pulmonary inflammation [26,27], the present study fails to report such activity; this may be attributed to insufficient doses utilized there. These results have suggested that blockade of Ang II receptors may be an important treatment option in the management of chronic asthma. Moreover, the predominant effect of telmisartan reported in the present study may be attributed to other mechanisms specifically

utilized by telmisartan, including effective PPAR- γ activation [28], while valsartan lacks such activity [29]. According to the outcome of the present study, the anti-inflammatory activity of telmisartan may not be attributed to the Ag II receptor blockade only, and other mechanisms might be involved including PPAR- γ agonist activity. Further studies are highly suggested to compare the activities of different ARB analogues in this model.

Acknowledgement

The data were abstracted from MSc thesis submitted by ManalAlgaem to the Department of Pharmacology and Toxicology, College of Pharmacy, University of Baghdad. The authors thank University of Baghdad for supporting the project.

References

- [1] Hao S, Baltimore D. The stability of mRNA influences the temporal order of the induction of genes encoding inflammatory molecules. *Nat. Immunol.*, 10(3):281-288. 2009.
- [2] Wagelie-Steffen AL, Kavanaugh AF, Wasserman IS. Biologic therapies for the treatment of asthma. *Clin. Chest Med.*, 103:36-42. 2006.
- [3] Fish JE, Peters SP. Airway remodeling and persistent airway obstruction in asthma. *J. Allergy Clin. Immunol.*, 104:509-551. 1999.
- [4] Gosens R, Bos IS, Zaagsma J, Meurs H. Protective effects of tiotropium bromide in the progression of airway smooth muscle remodeling. *Am. J. Respir. Crit. Care Med.*, 171:1096-1102. 2005.
- [5] Kakar SS, Sellers JC, Devor DC, Musgrove LC, Neill JD. Angiotensin II type-1 receptor subtype cDNAs: differential tissue expression and hormonal regulation. *Biochem. Biophys. Res. Commun.*, 183:1090-1096. 1992.
- [6] Kanazawa H, Kurihara N, Hirata K, Kudoh S, Fujii T, Tanaka S, et al. Angiotensin II stimulates peptide leukotriene production by guinea pig airway via the AT1 receptor pathway. *Prostaglandins Leukot. Essent. Fatty Acids*, 52: 241-244. 1995.
- [7] Gosens R, Zaagsma J, Meurs H, Halayko AJ. Muscarinic receptor signaling in the pathophysiology of asthma and COPD. *Respir. Res.*, 2006; 7:73. 2006.
- [8] Kramer C, Sunkomat J, Witte J, Luchtefeld M, Walden M, Schmidt B, et al. Angiotensin II receptor-independent anti-inflammatory and anti aggregatory properties of losartan role of the active metabolite exp3179. *Circ. Res.*, 90:770-776. 2002.
- [9] Stockley RA. Progression of chronic obstructive pulmonary disease: impact of inflammation, comorbidities and therapeutic intervention. *Curr. Med. Res. Opin.*, 25:1235-1245. 2009.
- [10] Marshall RP. The pulmonary renin-angiotensin system. *Curr. Pharm. Des.*, 9:715-722. 2003.
- [11] Chilosi M, Poletti V, Rossi A. The pathogenesis of COPD and IPF: distinct horns of the same devil? *Respir. Res.*, 13:3. 2012.
- [12] Jankowich MD, Rounds SIS. Combined pulmonary fibrosis and emphysema syndrome. *Chest*, 141:222-231. 2012.
- [13] Specks U, Martin WJ, Rohrbach MS. Bronchoalveolar lavage fluid angiotensin-converting enzyme in interstitial lung disease. *Am. Rev. Respir. Dis.*, 141:117-123. 1990.

- [14] Li X, Molina-Molina M, Abdul-Hafez A, Ramirez J, Serrano-Mollar A, Xaubet A, Uhal BD. Extravascular sources of lung angiotensin peptide synthesis in idiopathic pulmonary fibrosis. *Am. J. Physiol. Lung Cell. Mol. Physiol.*, 291:L887-L895. 2006.
- [15] Raupach T, Luthje L, Kogler H, Duve C, Schweda F, Hasenfuss G, Andreas S. Local and systemic effects of angiotensin receptor blockade in an emphysema mouse model. *Pulm.Pharmacol.Ther.*, 24:215-220. 2011.
- [16] Xue JM, Xu YJ, Zhang ZX, et al. Effects of nitric oxide on the airway inflammation and lymphocyte proliferation in sensitized rats. *Clin. J. Tuberc. Respir. Dis.*, 21:208-211. 1998.
- [17] Holsapple MP, Sehuner M, Yim GKW. Pharmacological modulation of edema mediated by prostaglandins, serotonin and histamine. *Agents Action*, 10:368-373. 1980.
- [18] Peter KG. Remodeling in asthma and chronic obstructive lung disease. *Am. J. Respir. Crit. Care Med.*, 28:28-38. 2001.
- [19] Brown AJ, Nally JE. Hydrocortisone abolishes the angiotensin II-mediated potentiation of endothelin-1 in bovine bronchi. *Clin. Sci. (London)*, 100(1):19-23. 2001.
- [20] Nally JE, Clayton RA, Wakelam MJ, Thomson NC, McGrath JC. Angiotensin II enhances responses to endothelin-1 in bovine bronchial smooth muscle. *Pulm.Pharmacol.*, 7(6):409-413. 1994.
- [21] Rao GN, Lassegue B, Alexander RW, Griendling KK. Angiotensin II stimulates phosphorylation of high-molecular-mass cytosolic phospholipase A2 in vascular smooth-muscle cells. *Biochem. J.*, 299:197-201. 1994.
- [22] Gijon MA, Leslie CC. Regulation of arachidonic acid release and cytosolic phospholipase A2 activation. *J. Leukoc. Biol.*, 65:330-336. 1999.
- [23] Rennard SI. Inflammation and repair processes in chronic obstructive pulmonary disease. *Am. J. Respir. Crit. Care Med.*, 160:S12-S16. 1999.
- [24] Elias JA, Zhu Z, Chupp G, Homer RJ. Airway remodeling in asthma. *J. Clin. Invest.*, 104:1001-1006. 1999.
- [25] Al-Hejjaj WK, Numan IT, Al-Sa'ad RZ, Hussain SA. Anti-inflammatory activity of telmisartan in rat models of experimentally-induced chronic inflammation: Comparative study with dexamethasone. *Saudi Pharm. J.*, 19:29-34. 2011.
- [26] Myou S, Fujimura M, Kurashima K, Tachibana H, Watanabe K, Hirose T. Type 1 angiotensin II receptor antagonism reduces antigen-induced airway reactions. *Am. J. Respir. Crit. Care Med.*, 162: 45-49. 2000.
- [27] Wang T, Yin KS, Liu KY, Lu GJ, Chen JD. Effect of valsartan on the expression of angiotensin II receptors in the lung of chronic antigen exposure rats. *Chin. Med. J.*, 121(22):2312-2319. 2008.
- [28] Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR γ -modulating activity. *Hypertension*, 43:993-1002. 2004.
- [29] Ushijima K, Takuma M, Ando H, Ishikawa-Kobayashi E, Nozawa M, Maekawa T, Shiga T, Fujimura A. Effects of telmisartan and valsartan on insulin sensitivity in obese diabetic mice. *Eur. J. Pharmacol.*, 5:698(1-3):505-510. 2013.